Fractyl Health, Inc. Common Stock

NASDAQ:GUTS

Biotechnology

Healthcare
$4.16 -0.81%

-$0.01 today

Market cap
$55.18M
Beta
2.34
P/E (TTM)
-0.6
EPS (TTM)
-$1.42
52W Low $0.38High $2.45

Volume 0.10M

Average 2.07M

GUTS Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Fractyl Health, Inc. Common StockNASDAQ: GUTS

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $15.6M fell 19.7% year over year, behind the -6.3% change in trailing-twelve-month research & development. Sequentially, it fell 5.4% from the prior quarter. Over 3 fiscal years it compounded at +29.5% a year.

Context

  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -19.7% toward the trailing-twelve-month pace of -6.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$15.6M-5.4% QoQ
Last fiscal yearDec 2025
$74.54M+5.8% YoY
LTMMar 2026
$70.7M-6.3% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-19.7%——
1 year+5.8%——
3-year CAGR+29.5%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
74.54M USD
Year-over-year change
+5.8%
4-year CAGR
+29.6%

Research & Development vs competitors

How GUTS compares with its peers on the latest reported figures

  • GUTS's LTM Mar 2026 research & development of $70.7M is the 3rd highest of the 7 companies compared; the peer median is $61.22M.
  • Its year-over-year change of -6.3% is the 3rd highest of 7, against a peer median of -24.7%.
  • Over three fiscal years its annual growth of +29.5% compares with a peer median of +6.1%.
GUTS Competitors Peer median
Research & Development for GUTS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STROSutro Biopharma, Inc.LTM Mar 2026$151.37M -38.7%+6.7%152.0%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$71.8M +27.7%+16.5%—
GUTSFractyl Health, Inc. Common StockLTM Mar 2026$70.7M -6.3%+29.5%—
ALXOALX Oncology Holdings Inc.LTM Mar 2026$66.71M -38.5%-7.9%—
ATYRaTyr Pharma, Inc.LTM Mar 2026$55.72M +5.5%+12.0%29327.4%
DTILPrecision BioSciences, Inc.LTM Mar 2026$53.36M -10.8%+5.5%118.4%
BMEABiomea Fusion, Inc.LTM Mar 2026$48.2M -55.0%-0.4%—
Peer median (excluding GUTS) $61.22M-24.7%+6.1%152.0%

Competitors are the stored peer set for GUTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00120K93K0
Cost of Revenue0452K77K50K0
Gross Profit0(452K)43K43K0
Gross Margin——35.8%46.2%—
Research & Development26.44M34.35M38.04M70.47M74.54M
Selling, General & Admin10.49M14.58M0022.28M
Operating Expenses36.93M48.93M50.88M93.57M96.82M
Depreciation & Amortization676K452K286K677K1.13M
EBITDA(36.62M)(46M)(76.81M)(68.02M)(139.83M)
EBITDA Margin——-64004.2%-73136.6%—
Operating Income(36.93M)(49.39M)(50.84M)(93.53M)(96.82M)
Operating Margin——-42363.3%-100571.0%—
Interest Income0797K1.26M4.15M1.54M
Interest Expense1.44M0000
Other Income / Expenses(1.81M)2.93M(26.26M)24.84M(44.14M)
Income Before Tax(38.74M)(46.45M)(77.09M)(68.69M)(140.95M)
Pre-Tax Margin——-64242.5%-73864.5%—
Income Tax Expense00000
Net Income(38.74M)(46.45M)(77.09M)(68.69M)(140.95M)
Net Margin——-64242.5%-73864.5%—
EPS (Basic)(1.12)(1.34)(1.98)(1.62)(1.86)
EPS (Diluted)(1.12)(1.34)(1.98)(1.62)(1.86)
Weighted Avg Shares47.61M47.61M47.61M43.54M75.82M
Weighted Avg Shares (Diluted)47.61M47.61M47.61M43.54M75.82M

Fractyl Health, Inc. Common Stock

NASDAQ:GUTS

Intrinsic Alpha fair value

Locked

Current Price

$4.16

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.